Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study

Publisher: Karger

E-ISSN: 1421-9913|72|3-4|173-180

ISSN: 0014-3022

Source: European Neurology, Vol.72, Iss.3-4, 2014-09, pp. : 173-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract